These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy. Gatica LV, Rosa AL. Neuromuscul Disord; 2016 Dec 12; 26(12):844-852. PubMed ID: 27816329 [Abstract] [Full Text] [Related]
12. Facioscapulohumeral muscular dystrophy (FSHD): an enigma unravelled? Richards M, Coppée F, Thomas N, Belayew A, Upadhyaya M. Hum Genet; 2012 Mar 12; 131(3):325-40. PubMed ID: 21984394 [Abstract] [Full Text] [Related]
13. [Facioscapulohumeral muscular dystrophy type 2]. Sacconi S, Desnuelle C. Rev Neurol (Paris); 2013 Mar 12; 169(8-9):564-72. PubMed ID: 23969240 [Abstract] [Full Text] [Related]
16. Molecular basis of facioscapulohumeral muscular dystrophy. Tupler R, Gabellini D. Cell Mol Life Sci; 2004 Mar 12; 61(5):557-566. PubMed ID: 15004695 [Abstract] [Full Text] [Related]
17. CRISPR/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy. Himeda CL, Jones TI, Jones PL. Mol Ther; 2016 Mar 12; 24(3):527-35. PubMed ID: 26527377 [Abstract] [Full Text] [Related]
19. Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Osborne RJ, Welle S, Venance SL, Thornton CA, Tawil R. Neurology; 2007 Feb 20; 68(8):569-77. PubMed ID: 17151338 [Abstract] [Full Text] [Related]